Home / Business and Economy / India's Pharma Giants Tap Into Global Drug Discovery Boom
India's Pharma Giants Tap Into Global Drug Discovery Boom
3 Oct
Summary
- India's CRDMO industry is projected for 15% annual growth.
- Jubilant Pharmova expands capacity with US$150 million capex.
- Sai Life Science repays debt, reducing leverage significantly post-IPO.
India's drug discovery and contract research market is advancing, with global pharmaceutical firms increasingly outsourcing early-stage research and discovery chemistry to Contract Research Organisations (CROs).
This trend is creating significant opportunities for integrated providers like Contract Development and Manufacturing Organisations (CDMOs) and Contract Research, Development, and Manufacturing Organisations (CRDMOs).
ICRA forecasts India's CRDMO industry to grow at approximately 15% annually for the next decade, though it currently holds a small share of the global market.
Jubilant Pharmova is expanding its capacity with a US$150 million investment, aiming to double its workforce by FY28, while managing increased net debt.
Sai Life Science, following its IPO, has substantially reduced its leverage and is investing heavily in capacity expansion, focusing on both CRO and CDMO services.
The companies face challenges including scientific program failures, AI-driven changes in discovery economics, and competition from China.
Government initiatives like the PRIP scheme provide support for R&D, but company-level execution remains crucial for commercial success.
